Back

Effects of NMDA antagonists on social behaviour: a systematic review and meta-analysis of preclinical studies

Gallas-Lopes, M.; Abreu, M. B.; Andrades, M.; Arbo, B. D.; Bastos, L. M.; Caetano, T. C.; Muller, D. V.; Patelli-Alves, A.; Rosa, D. A.; Stein, D. J.; Herrmann, A. P.

2026-05-15 pharmacology and toxicology
10.64898/2026.05.13.724847 bioRxiv
Show abstract

Social withdrawal is a key component of the negative symptom domain of schizophrenia, and pharmacological blockade of the N-methyl-D-aspartate receptor (NMDAR) is widely used to model schizophrenia-relevant phenotypes in animals. However, findings on social behaviour are inconsistent across paradigms and laboratories. We therefore conducted a systematic review and meta-analysis to synthesise the effects of dizocilpine, ketamine, and phencyclidine on social interaction and social preference, to evaluate whether clinically approved antipsychotics modify these outcomes, and to examine locomotor activity measured within the same social tests to aid interpretation. We searched Embase, PubMed and Web of Science without language or date restrictions. Controlled in vivo studies in laboratory animals administering an eligible NMDAR antagonist and reporting social interaction and/or social preference outcomes were included. Two reviewers independently screened records, extracted data and assessed risk of bias. Effect sizes were computed as standardised mean differences and synthesised using correlated multilevel random-effects models with cluster-robust variance estimation. In total, 264 studies met the inclusion criteria. Overall, NMDAR antagonists were associated with reduced social interaction and reduced social preference relative to controls, although the social preference literature appeared vulnerable to small-study effects and imprecision. Locomotor activity measured during social interaction tests tended to be higher following NMDAR antagonists, whereas during social preference no consistent overall change was observed. In animals exposed to NMDAR antagonists, antipsychotics increased social behaviour, but these changes commonly co-occurred with reduced locomotion during social interaction tests, suggesting that improvements in social measures may partly reflect altered behavioural competition and time allocation rather than selective restoration of social functioning. Taken together, the evidence supports an overall link between NMDAR antagonism and reduced social behaviour, but the strength and interpretability of this signal depend on the paradigm and are constrained by heterogeneity and limitations in reporting.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Neuropsychopharmacology
134 papers in training set
Top 0.3%
10.0%
2
Schizophrenia Bulletin
29 papers in training set
Top 0.2%
6.8%
3
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 0.2%
6.3%
4
Brain, Behavior, and Immunity
105 papers in training set
Top 0.4%
6.3%
5
PLOS ONE
4510 papers in training set
Top 31%
4.8%
6
Frontiers in Pharmacology
100 papers in training set
Top 0.5%
4.8%
7
Schizophrenia
19 papers in training set
Top 0.1%
4.8%
8
Schizophrenia Research
29 papers in training set
Top 0.2%
4.3%
9
Frontiers in Psychiatry
83 papers in training set
Top 0.8%
4.3%
50% of probability mass above
10
Translational Psychiatry
219 papers in training set
Top 1%
4.3%
11
Scientific Reports
3102 papers in training set
Top 37%
3.6%
12
Journal of Psychopharmacology
14 papers in training set
Top 0.1%
3.6%
13
The British Journal of Psychiatry
21 papers in training set
Top 0.2%
3.6%
14
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.1%
3.6%
15
Drug and Alcohol Dependence
37 papers in training set
Top 0.3%
2.6%
16
Molecular Psychiatry
242 papers in training set
Top 1%
2.6%
17
Epilepsia
49 papers in training set
Top 0.5%
1.9%
18
Psychopharmacology
59 papers in training set
Top 0.4%
1.7%
19
Psychological Medicine
74 papers in training set
Top 1%
1.5%
20
European Journal of Neuroscience
168 papers in training set
Top 0.6%
1.5%
21
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.6%
1.2%
22
Neurobiology of Disease
134 papers in training set
Top 3%
1.2%
23
Biological Psychiatry Global Open Science
54 papers in training set
Top 1.0%
1.2%
24
British Journal of Pharmacology
34 papers in training set
Top 0.5%
0.8%
25
Biological Psychiatry
119 papers in training set
Top 2%
0.8%
26
JAMA Psychiatry
13 papers in training set
Top 0.6%
0.7%
27
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.6%